Long Noncoding RNA CCDC26 Promotes Thyroid Cancer Malignant Progression via miR-422a/EZH2/Sirt6 Axis

References

• Janjua N, Wreesmann VB. Aggressive differentiated thyroid cancer. Eur J Surg Oncol. 2018;44(3):367–377. doi:10.1016/j.ejso.2017.09.019
   PubMed Web of Science ®Google Scholar
• Sharifi A, Shojaeifard A, Soroush A, Jafari M, Abdehgah AG, Mahmoudzade H. Predictors of regional lymph node recurrence after initial thyroidectomy in patients with thyroid cancer. J Thyroid Res. 2016;2016:4127278. doi:10.1155/2016/4127278
   PubMedGoogle Scholar
• Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983–2007. Asia Pac J Public Health. 2015;27(2):NP223–229. doi:10.1177/1010539512436874
   PubMed Web of Science ®Google Scholar
• Carlberg M, Hedendahl L, Ahonen M, Koppel T, Hardell L. Increasing incidence of thyroid cancer in the Nordic countries with main focus on Swedish data. BMC Cancer. 2016;16:426. doi:10.1186/s12885-016-2429-4
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–199. doi:10.1038/nrc3431
   PubMed Web of Science ®Google Scholar
• Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524–531. doi:10.1002/cncr.21653
   PubMed Web of Science ®Google Scholar
• Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated thyroid cancer-treatment: state of the art. Int J Mol Sci. 2017;18(6). doi:10.3390/ijms18061292
   PubMed Web of Science ®Google Scholar
• Naoum GE, Morkos M, Kim B, Arafat W. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol Cancer. 2018;17(1):51. doi:10.1186/s12943-018-0786-0
   PubMedGoogle Scholar
• Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661–5667. doi:10.1038/onc.2017.184
   PubMed Web of Science ®Google Scholar
• Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172(3):393–407. doi:10.1016/j.cell.2018.01.011
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981. doi:10.1158/0008-5472.CAN-16-2634
   PubMed Web of Science ®Google Scholar
• Liu X, Fu Q, Li S, et al. LncRNA FOXD2-AS1 functions as a competing endogenous RNA to Regulate TERT expression by sponging miR-7-5p in thyroid cancer. Front Endocrinol (Lausanne). 2019;10:207. doi:10.3389/fendo.2019.00207
   PubMed Web of Science ®Google Scholar
• Hou S, Lin Q, Guan F, Lin C. LncRNA TNRC6C-AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR-129-5p. J Cell Biochem. 2018;119(10):8304–8316. doi:10.1002/jcb.26868
   PubMed Web of Science ®Google Scholar
• Zheng W, Tian X, Cai L, et al. LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer. Eur Rev Med Pharmacol Sci. 2019;23(23):10443–10452. doi:10.26355/eurrev_201912_19683
   PubMed Web of Science ®Google Scholar
• Peng W, Jiang A. Long noncoding RNA CCDC26 as a potential predictor biomarker contributes to tumorigenesis in pancreatic cancer. Biomed Pharmacother. 2016;83:712–717. doi:10.1016/j.biopha.2016.06.059
   PubMed Web of Science ®Google Scholar
• Izadifard M, Pashaiefar H, Yaghmaie M, et al. Expression analysis of PVT1, CCDC26, and CCAT1 long noncoding RNAs in acute myeloid leukemia patients. Genet Test Mol Biomarkers. 2018;22(10):593–598. doi:10.1089/gtmb.2018.0143
   PubMed Web of Science ®Google Scholar
• Li D, Wang X, Lu S, et al. Integrated analysis revealing genome-wide chromosomal copy number variation in supraglottic laryngeal squamous cell carcinoma. Oncol Lett. 2020;20(2):1201–1212. doi:10.3892/ol.2020.11653
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–1207. doi:10.1016/j.jaci.2017.08.034
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222. doi:10.1038/nrd.2016.246
   PubMed Web of Science ®Google Scholar
• Zhou Q, Huang SX, Zhang F, et al. MicroRNAs: a novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif. 2017;50(6). doi:10.1111/cpr.12394.
   Web of Science ®Google Scholar
• Ghafouri-Fard S, Shirvani-Farsani Z, Taheri M. The role of microRNAs in the pathogenesis of thyroid cancer. Noncoding RNA Res. 2020;5(3):88–98. doi:10.1016/j.ncrna.2020.06.001
   PubMed Web of Science ®Google Scholar
• Wen HL, Xu ZM, Lin SY, Wen D, Xie JP. miR-597-3p inhibits invasion and migration of thyroid carcinoma SW579 cell by targeting RAB23. Endokrynol Pol. 2020. doi:10.5603/EP.a2020.0041
   PubMed Web of Science ®Google Scholar
• Luo L, Xia L, Zha B, et al. miR-335-5p targeting ICAM-1 inhibits invasion and metastasis of thyroid cancer cells. Biomed Pharmacother. 2018;106:983–990. doi:10.1016/j.biopha.2018.07.046
   PubMed Web of Science ®Google Scholar
• Li WQ, Zhang JP, Wang YY, Li XZ, Sun L. MicroRNA-422a functions as a tumor suppressor in non-small cell lung cancer through SULF2-mediated TGF-beta/SMAD signaling pathway. Cell Cycle. 2019;18(15):1727–1744. doi:10.1080/15384101.2019.1632135
   PubMed Web of Science ®Google Scholar
• Zhang X, Gao D, Fang K, Guo Z, Li L. Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway. Cancer Lett. 2019;444:105–115. doi:10.1016/j.canlet.2018.12.008
   PubMed Web of Science ®Google Scholar
• Yan DG, Liu N, Chao M, Tu YY, Liu WS. SP1-induced upregulation of long noncoding RNA LINC00313 contributes to papillary thyroid cancer progression via the miR-422a. Eur Rev Med Pharmacol Sci. 2019;23(3):1134–1144. doi:10.26355/eurrev_201902_17004
   PubMed Web of Science ®Google Scholar
• Wang J, Yang H, Si Y, et al. Iodine promotes tumorigenesis of thyroid cancer by suppressing Mir-422a and up-regulating MAPK1. Cell Physiol Biochem. 2017;43(4):1325–1336. doi:10.1159/000481844
   PubMedGoogle Scholar
• Chen Y, Hong T, Wang S, Mo J, Tian T, Zhou X. Epigenetic modification of nucleic acids: from basic studies to medical applications. Chem Soc Rev. 2017;46(10):2844–2872. doi:10.1039/C6CS00599C
   PubMed Web of Science ®Google Scholar
• Esposito F, Tornincasa M, Pallante P, et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab. 2012;97(5):E710–718. doi:10.1210/jc.2011-3068
   PubMed Web of Science ®Google Scholar
• Yu W, Yang Z, Huang R, Min Z, Ye M. SIRT6 promotes the Warburg effect of papillary thyroid cancer cell BCPAP through reactive oxygen species. Onco Targets Ther. 2019;12:2861–2868. doi:10.2147/OTT.S194256
   PubMed Web of Science ®Google Scholar
• Zhao W, Han T, Li B, Ma Q, Yang P, Li H. miR-552 promotes ovarian cancer progression by regulating PTEN pathway. J Ovarian Res. 2019;12(1):121. doi:10.1186/s13048-019-0589-y
   PubMed Web of Science ®Google Scholar
• Chen Y, Gao Y, Lian Y, Li C, Qu C, Jiang X. Overexpression of miR-221 stimulates proliferation of rat neural stem cell with activating Phosphatase and tensin homolog/protein kinase B signaling pathway. Neuroreport. 2020;31(14):1015–1023. doi:10.1097/WNR.0000000000001513
   PubMed Web of Science ®Google Scholar
• Zou YT, Gao JY, Wang HL, Wang Y, Wang H, Li PL. Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma. Genet Mol Res. 2015;14(3):8766–8777. doi:10.4238/2015.July.31.25
   PubMed Web of Science ®Google Scholar
• Kelly TJ, Suzuki HI, Zamudio JR, Suzuki M, Sharp PA. Sequestration of microRNA-mediated target repression by the Ago2-associated RNA-binding protein FAM120A. RNA. 2019;25(10):1291–1297. doi:10.1261/rna.071621.119
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783–2795. doi:10.1016/S0140-6736(16)30172-6
   PubMed Web of Science ®Google Scholar
• Carling T, Udelsman R. Thyroid cancer. Annu Rev Med. 2014;65:125–137. doi:10.1146/annurev-med-061512-105739
   PubMed Web of Science ®Google Scholar
• Yan J, Chen D, Chen X, et al. Downregulation of lncRNA CCDC26 contributes to imatinib resistance in human gastrointestinal stromal tumors through IGF-1R upregulation. Braz J Med Biol Res. 2019;52(6):e8399. doi:10.1590/1414-431x20198399
   PubMed Web of Science ®Google Scholar
• Cao K, Li M, Miao J, et al. CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT. Am J Transl Res. 2018;10(1):274–282.
   PubMed Web of Science ®Google Scholar
• Wang S, Hui Y, Li X, Jia Q. Silencing of lncRNA CCDC26 restrains the growth and migration of glioma cells in vitro and in vivo via targeting miR-203. Oncol Res. 2018;26(8):1143–1154. doi:10.3727/096504017X14965095236521
   PubMed Web of Science ®Google Scholar
• Hirano T, Yoshikawa R, Harada H, Harada Y, Ishida A, Yamazaki T. Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression. Mol Cancer. 2015;14:90. doi:10.1186/s12943-015-0364-7
   PubMed Web of Science ®Google Scholar
• Wang S, Wu J, Ren J, et al. MicroRNA-125b interacts with Foxp3 to induce autophagy in thyroid cancer. Mol Ther. 2018;26(9):2295–2303. doi:10.1016/j.ymthe.2018.06.015
   PubMed Web of Science ®Google Scholar
• Yi T, Zhou X, Sang K, Zhou J, Ge L. MicroRNA-1270 modulates papillary thyroid cancer cell development by regulating SCAI. Biomed Pharmacother. 2019;109:2357–2364. doi:10.1016/j.biopha.2018.08.150
   PubMed Web of Science ®Google Scholar
• Luo Y, Hao T, Zhang J, Zhang M, Sun P, Wu L. MicroRNA-592 suppresses the malignant phenotypes of thyroid cancer by regulating lncRNA NEAT1 and downregulating NOVA1. Int J Mol Med. 2019;44(3):1172–1182. doi:10.3892/ijmm.2019.4278
   PubMed Web of Science ®Google Scholar
• Lu Z, Wu Z, Hu J, Wei W, Ma B, Wen D. MicroRNA-15 regulates the proliferation, migration and invasion of thyroid cancer cells by targeting Bcl-2. J BUON. 2019;24(5):2114–2119.
   PubMed Web of Science ®Google Scholar
• Xue L, Yan H, Chen Y, et al. EZH2 upregulation by ERalpha induces proliferation and migration of papillary thyroid carcinoma. BMC Cancer. 2019;19(1):1094. doi:10.1186/s12885-019-6306-9
   PubMed Web of Science ®Google Scholar
• Yang Z, Yu W, Huang R, Ye M, Min Z. SIRT6/HIF-1alpha axis promotes papillary thyroid cancer progression by inducing epithelial-mesenchymal transition. Cancer Cell Int. 2019;19:17. doi:10.1186/s12935-019-0730-4
   PubMed Web of Science ®Google Scholar
• Qu N, Hu JQ, Liu L, et al. SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl1 pathway. Int J Oncol. 2017;50(5):1683–1692. doi:10.3892/ijo.2017.3951
   PubMed Web of Science ®Google Scholar